Volume | 869,000 |
|
|||||
News | - | ||||||
Day High | 9.24 | Low High |
|||||
Day Low | 8.825 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Marinus Pharmaceuticals Inc | MRNS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.91 | 8.825 | 9.24 | 9.04 | 8.85 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,586 | 869,000 | $ 9.00 | $ 7,819,601 | - | 5.5704 - 11.26 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:38:23 | 3 | $ 8.94 | USD |
Marinus Pharmaceuticals (MRNS) Options Flow Summary
Marinus Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
493.42M | 54.64M | - | 30.99M | -141.41M | -2.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Marinus Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.07 | 9.41 | 8.49 | 8.88 | 404,455 | -0.03 | -0.33% |
1 Month | 10.02 | 10.50 | 8.15 | 9.09 | 549,474 | -0.98 | -9.78% |
3 Months | 9.75 | 11.26 | 8.15 | 9.67 | 426,441 | -0.71 | -7.28% |
6 Months | 7.98 | 11.26 | 5.5704 | 8.63 | 433,403 | 1.06 | 13.28% |
1 Year | 6.25 | 11.26 | 5.5704 | 8.56 | 612,667 | 2.79 | 44.64% |
3 Years | 14.54 | 19.83 | 3.465 | 8.50 | 406,919 | -5.50 | -37.83% |
5 Years | 3.84 | 20.04 | 0.77 | 4.71 | 962,975 | 5.20 | 135.42% |
Marinus Pharmaceuticals Description
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. |